SDC1 and Miyoshi myopathy: In order to determine whether TI17 has anti‐MM activity on patient MM cells, we detected the effect of TI17 on patients CD138+ MM cells by flow cytometry analysis, and our findings showed that TI17 induced a significant dose‐dependent increase apoptosis in primary CD138+ MM cells, while have no cytotoxic effect on CD138− MM cells (Figure 5C,D), as well as normal PBMCs (Figure 5E,F), indicating TI17 is a favorable therapeutic index in MM.